Top

Published in:

01-03-2012 | Review Article

Cognitive impairment in antiphospholipid syndrome: evidence from animal models

Authors: Simone Appenzeller, Aline Tamires Lapa, Caio Rodrigues Guirau, Jozélio Freire de Carvalho, Yehuda Shoenfeld

Published in: Clinical Rheumatology | Issue 3/2012

Abstract

Although antiphospholipid syndrome (APS) is a multisystem prothrombotic condition, its inflammatory nature has been increasingly recognized in recent years. Stroke and transitory ischemic attacks are the neurological manifestations included in APS criteria, however many other neurological involvements have been attributed to antiphospholipid antibodies (aPL), such as seizures, transverse myelitis, and cognitive impairment. In this article we will review evidence from animal model that explain the role of aPL in cognition.

Wilson WA, Gharavi AE, Koike T et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311PubMedCrossRef

Miyakis S, Lockshin MD, Atsumi T, Branch DC, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemostasis 4:295–306CrossRef

Chapman J, Rand JH, Brey RL, Levine SR, Blatt I, Khamashta MA, Shoenfeld Y (2003) Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus 12:514–517PubMedCrossRef

Sanna G, Bertolaccini ML, Cuadrado MJ et al (2003) Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology 42:200–213PubMedCrossRef

Tomietto P, Annese V, D'agostini S, Venturini P, La Torre G, De Vita S, Ferraccioli GF (2007) General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Rheum 57:1461–1472PubMedCrossRef

Mikdashi J, Handwerger B (2004) Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology (Oxford) 43:1555–1560CrossRef

McLaurin EY, Holliday SL, Williams P, Brey RL (2005) Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 64:297–303PubMedCrossRef

Tektonidou MG, Varsou N, Kotoulas G, Antoniou A, Moutsopouls HM (2006) Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging finding. Arch Int Med 166:2278–2284CrossRef

Aharon-Peretz J, Brenner B, Amyel E et al (1995) Neurocgnitive dysfunction in antiphospholipid antibody syndrome (APS). Lupus 4:101

10.

Erkan D, Kozora E, Lockshin MD (2011) Cognitive dysfunction and white matter abnormalities in antiphospholipid syndrome. Pathophysiology 18:93–102PubMedCrossRef

11.

Chapman J, Abu-Katash M, Inzelberg R et al (2002) Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J Neurol Sci 203–204:81–84PubMedCrossRef

12.

Levine SR, Welch KMA (1987) The spectrum of neurologic disease associated with antiphospholipid antibodies. Lupus anticoagulants and anticardiolipin antibodies. Arch Neurol 44:876–883PubMedCrossRef

13.

Liberato B, Levy RA (2007) Antiphospholipid syndrome and cognition. Clin Rev Allergy Immunol 32:188–191PubMedCrossRef

14.

Hess DC, Taormina M, Thompson J et al (1993) Cognitive and neurologic deficits in the MRL/lpr mouse: a clinicopathologic study. J Rheumatol 20:610–617PubMed

15.

Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD (1997) Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest 100:613–9.10PubMedCrossRef

16.

Shoenfeld Y, Nahum A, Korczyn AD et al (2003) Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 12:436–442PubMedCrossRef

17.

Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD (1999) Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 8:127–133PubMedCrossRef

18.

Cimaz R, Meroni PL, Shoenfeld Y (2006) Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipidsyndrome (Hughe’s syndrome). Lupus 15:191–197PubMedCrossRef

19.

Appenzeller S, Cendes F, Costallat LT (2004) Epileptic seizures in systemic lupus erythematosus. Neurology 63:1808–1812PubMed

20.

Herranz MT, Rivier G, Khamashta MA, Blaser KU, Hughes GR (1994) Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 37:568–571PubMedCrossRef

21.

Katzav A, Litvinjuk Y, Pick CG et al (2006) Genetic and immunological factors interact in a mouse model of CNS antiphospholipid syndrome. Behav Brain Res 169:289–293PubMedCrossRef

22.

Chapman J, Shoenfeld Y (2002) Neurological and neuroendocrine-cytokine inter-relationship in the antiphospholipid syndrome. Ann N Y Acad Sci 966:415–424PubMedCrossRef

23.

Katzav A, Shrot S, Litvinjuk Y et al (2001) Cognitive and behavioral deficits develop late in a mouse model of the antiphospholipid syndrome (APS). Neurology 56:A472

24.

Shrot S, Katzav A, Korczyn AD et al (2002) Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus 11:736–743PubMedCrossRef

25.

Aron AL, Cuellar ML, Brey RL et al (1995) Early onset of autoimmunity in MRL/++ mice following immunization with beta 2 glycoprotein I. Clin Exp Immunol 101:78–81PubMedCrossRef

26.

Katzav A, Shoenfeld Y, Chapman J (2010) The pathogenesis of neural injury in animal models of the antiphospholipid syndrome. Clin Rev Allergy Immunol 38:196–200PubMedCrossRef

27.

Nowacki P, Ronin-Walknowska E, Ossowicka-Stepinska J (1998) Central nervous system involvement in pregnant rabbits with experimental model of antiphospholipid syndrome. Folia Neuropathol 36:38–44PubMed

28.

Nowacki P, Ronin-Walknowska E, Ossowicka-Stepinska J (1999) Neuropathological changes within the brain of rabbits with experimental model of antiphospholipid syndrome in different time after immunization. Folia Neuropathol 37:269–272PubMed

29.

Meroni PL, Raschi E, Testoni C (2002) Endothelium as a target for anti-phospholipid antibodies and for therapeutical intervention. Autoimmun Rev 1:55–60PubMedCrossRef

30.

Pierangeli SS, Chen PP, Raschi E et al (2008) Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 34:236–250PubMedCrossRef

31.

Soltesz P, Der H, Veres K et al (2008) Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction. Rheumatology (Oxford) 47:1628–1634CrossRef

Title: Cognitive impairment in antiphospholipid syndrome: evidence from animal models
Authors: Simone Appenzeller
Aline Tamires Lapa
Caio Rodrigues Guirau
Jozélio Freire de Carvalho
Yehuda Shoenfeld
Publication date: 01-03-2012
Publisher: Springer-Verlag
Published in: Clinical Rheumatology / Issue 3/2012
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-011-1922-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Successful treatment of adult-onset Still’s disease with tocilizumab monotherapy: two case reports and literature review

The pathway of estradiol-induced apoptosis in patients with systemic lupus erythematosus

Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis

Effect of music on anxiety and pain during joint lavage for knee osteoarthritis

Chilblain lupus induced by TNF-α antagonists: a case report and literature review

Incidental computed tomography sacroiliitis: clinical significance and inappropriateness of the New York radiological grading criteria for the diagnosis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials